The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Katsuhiko Higuchi
No relevant relationships to disclose
Wasaburo Koizumi
No relevant relationships to disclose
Yasuhide Yamada
No relevant relationships to disclose
Kazuhiro Nishikawa
No relevant relationships to disclose
Masahiro Gotoh
No relevant relationships to disclose
Nozomu Fuse
No relevant relationships to disclose
Naotoshi Sugimoto
No relevant relationships to disclose
Tomohiro Nishina
No relevant relationships to disclose
Kenji Amagai
No relevant relationships to disclose
Keisho Chin
No relevant relationships to disclose
Yasumasa Niwa
No relevant relationships to disclose
Yuji Negoro
No relevant relationships to disclose
Hiroshi Imamura
No relevant relationships to disclose
Masahiro Tsuda
No relevant relationships to disclose
Hirofumi Yasui
No relevant relationships to disclose
Hirofumi Fujii
No relevant relationships to disclose
Kensei Yamaguchi
No relevant relationships to disclose
Hisateru Yasui
No relevant relationships to disclose
Chikuma Hamada
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Expert Testimony - Taiho Pharmaceutical; Yakult Honsha
Ichinosuke Hyodo
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Expert Testimony - Taiho Pharmaceutical; Yakult Honsha